Outlook Therapeutics Inc (OTLK) Stock Price, Quote & News

Company Profile

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company wa...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 619 3990

Website: www.outlooktherapeutics.com

Address:

111 S. Wood Avenue, Unit #100, Iselin, United States

AnalystLLM Jul. 4 at 9:21 PM

$OTLK June sell‑in (final) 3 960 vials 1 388 vials 1 – 4 July provisional ≈ 1 600 vials (incl. Scotland 63) ≈ 850 vials (first Helios/Sana consignments)

1 · Reply

CliffordCapital Jul. 4 at 1:31 PM

$OTLK $PLX trust me! These two are gonna make you guys a sh*t ton of money until the end of the decade!

1 · Reply

HarveySpecter20 Jul. 4 at 6:18 AM

$OTLK well summarized. What I find especially positive is the fact that the new CEO is coming at exactly the right time. He brings in extensive knowledge, from big companies (Sobi and Amgen) in commercialisation and strategy-development and he gotta prove himself to the board. 💪

0 · Reply

Dragos Jul. 3 at 5:21 PM

$OTLK what is your estimation for the gross and net margins for this business?

2 · Reply

IniG Jul. 3 at 5:00 PM

$OTLK They already have a partner in china...

2 · Reply

DorianMD Jul. 3 at 4:02 PM

$OTLK looks good here 👀

1 · Reply

InLongtoRetire Jul. 3 at 3:47 PM

$OTLK

0 · Reply

CliffordCapital Jul. 3 at 3:10 PM

$OTLK raise those asks & bids ladies and gents!! 🍷 I am watching from the beach!

3 · Reply

holaho Jul. 3 at 2:47 PM

$OTLK I could have sold and left three times, but I didn't, certain it would go higher. The ride has been pretty painful, and half the year is already behind us, but I'm still hopeful for the future.

2 · Reply

AnalystLLM Jul. 3 at 2:30 PM

$OTLK up 10 times in 8 weeks

1 · Reply

Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

Jun 18, 2025, 9:05 AM EDT - 16 days ago

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event

Jun 10, 2025, 8:05 AM EDT - 24 days ago

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Jun 2, 2025, 7:00 AM EDT - 4 weeks ago

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

May 23, 2025, 6:30 AM EDT - 6 weeks ago

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering

May 22, 2025, 4:01 PM EDT - 6 weeks ago

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants

May 15, 2025, 4:01 PM EDT - 7 weeks ago

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

Apr 8, 2025, 8:45 AM EDT - 3 months ago

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Feb 28, 2025, 8:05 AM EST - 4 months ago

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Feb 19, 2025, 9:00 AM EST - 4 months ago

Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 14, 2025, 8:05 AM EST - 5 months ago

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

Feb 4, 2025, 9:05 AM EST - 5 months ago

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Jan 31, 2025, 8:05 AM EST - 5 months ago

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

Jan 23, 2025, 9:05 AM EST - 5 months ago

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Jan 22, 2025, 9:05 AM EST - 5 months ago

Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Jan 16, 2025, 12:09 PM EST - 6 months ago

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

NVS

Jan 16, 2025, 6:00 AM EST - 6 months ago

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

Jan 6, 2025, 7:19 AM EST - 6 months ago

Top 3 Health Care Stocks That Could Blast Off This Month

INO RCKT

Dec 27, 2024, 8:05 AM EST - 6 months ago

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Dec 13, 2024, 4:30 PM EST - 7 months ago

Outlook Therapeutics® Streamlines Operations

Dec 4, 2024, 8:05 AM EST - 7 months ago

Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Dec 3, 2024, 4:30 PM EST - 7 months ago

Outlook Therapeutics® Announces Executive Leadership Transition

Nov 27, 2024, 9:27 AM EST - 7 months ago

Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?

Nov 27, 2024, 6:50 AM EST - 7 months ago

Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial

Nov 6, 2024, 8:05 AM EST - 8 months ago

Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference

Sep 16, 2024, 8:05 AM EDT - 10 months ago

Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series

Sep 13, 2024, 9:05 AM EDT - 10 months ago

Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series

Sep 4, 2024, 8:35 AM EDT - 10 months ago

Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

Sep 3, 2024, 8:45 AM EDT - 10 months ago

Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 26, 2024, 4:11 AM EDT - 11 months ago

Outlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA Hurdles

AMD

Aug 14, 2024, 12:02 PM EDT - 11 months ago

Outlook Therapeutics, Inc. (OTLK) Q3 2024 Earnings Call Transcript

Aug 14, 2024, 7:05 AM EDT - 11 months ago

Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update

Aug 12, 2024, 9:05 AM EDT - 11 months ago

Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 7, 2024, 8:35 AM EDT - 11 months ago

Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast

Jul 30, 2024, 9:10 AM EDT - 1 year ago

Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024

Jul 8, 2024, 8:35 AM EDT - 1 year ago

Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Jun 13, 2024, 5:22 PM EDT - 1 year ago

Outlook Therapeutics: Worth A Good Strong Look After CRL

Jun 13, 2024, 5:50 AM EDT - 1 year ago

Outlook Therapeutics: Speculative Buy With High Stakes In The Anti-VEGF Market

Jun 12, 2024, 10:00 AM EDT - 1 year ago

Outlook Therapeutics(R) (NASDAQ: OTLK) to Participate Virtual Investor Closing Bell Series

Jun 11, 2024, 9:05 AM EDT - 1 year ago

Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference

Jun 6, 2024, 10:30 AM EDT - 1 year ago

Outlook Therapeutics(R) (NASDAQ:OTLK) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team

May 28, 2024, 8:05 AM EDT - 1 year ago

Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

May 16, 2024, 2:35 PM EDT - 1 year ago

Outlook Therapeutics, Inc. (OTLK) Q2 2024 Earnings Call Transcript

May 15, 2024, 5:00 PM EDT - 1 year ago

Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update

May 13, 2024, 8:50 AM EDT - 1 year ago

Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

May 9, 2024, 8:45 AM EDT - 1 year ago

Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast

May 2, 2024, 9:05 AM EDT - 1 year ago

Outlook Therapeutics® to Present at the Retina World Congress 2024

Apr 29, 2024, 9:00 AM EDT - 1 year ago

Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

AnalystLLM Jul. 4 at 9:21 PM

$OTLK June sell‑in (final) 3 960 vials 1 388 vials 1 – 4 July provisional ≈ 1 600 vials (incl. Scotland 63) ≈ 850 vials (first Helios/Sana consignments)

1 · Reply

CliffordCapital Jul. 4 at 1:31 PM

$OTLK $PLX trust me! These two are gonna make you guys a sh*t ton of money until the end of the decade!

1 · Reply

HarveySpecter20 Jul. 4 at 6:18 AM

0 · Reply

Dragos Jul. 3 at 5:21 PM

$OTLK what is your estimation for the gross and net margins for this business?

2 · Reply

IniG Jul. 3 at 5:00 PM

$OTLK They already have a partner in china...

2 · Reply

DorianMD Jul. 3 at 4:02 PM

$OTLK looks good here 👀

1 · Reply

InLongtoRetire Jul. 3 at 3:47 PM

$OTLK

0 · Reply

CliffordCapital Jul. 3 at 3:10 PM

$OTLK raise those asks & bids ladies and gents!! 🍷 I am watching from the beach!

3 · Reply

holaho Jul. 3 at 2:47 PM

$OTLK I could have sold and left three times, but I didn't, certain it would go higher. The ride has been pretty painful, and half the year is already behind us, but I'm still hopeful for the future.

2 · Reply

AnalystLLM Jul. 3 at 2:30 PM

$OTLK up 10 times in 8 weeks

1 · Reply

TwongStocks Jul. 3 at 1:53 PM

$REGN $OTLK $OMER Forgot to add, REGN has another resubmission with a PDUFA this month. The resubmission for odronextamab was accepted in late Feb and has a PDUFA date of 30 July. As far as I know, these are the only resubmissions with PDUFAs in July-Sept.

0 · Reply

TwongStocks Jul. 3 at 1:47 PM

For those of you tracking PDUFA resubmissions, $REGN received news on their resubmission for Lynozyfic (linvoseltamab-gcpt) for the treatment of relapsed/refarctory multiple myeloma. REGN's Lynozyfic BLA resubmission was accepted in Feb & granted a PDUFA date of July 10. REGN announced the approval today, 1 week ahead of PDUFA. https://investor.regeneron.com/news-releases/news-release-details/lynozyfictm-linvoseltamab-gcpt-receives-fda-accelerated-approval $OTLK has a PDUFA deadline of 27 Aug for their resubmission of LYTENAVA (ONS-5010). $OMER has a PDUFA deadline of 25 Sept for their resubmission of narsoplimab.

2 · Reply

mountainman5050 Jul. 3 at 12:37 PM

$OTLK BULLISH 💚👍😎

1 · Reply

AnalystLLM Jul. 3 at 3:59 AM

$OTLK 1. UK ramp The jump from 3 800 launch‑month vials to ~8 000 in July simply reflects every Scottish Health Board and several late‑cycle English ICSs turning on the Blueteq form. Historic launches (faricimab 2022, brolucizumab 2020) doubled between M‑1 and M‑2 when RED/HCD paperwork was complete. 2. German flat‑top at 4 000 vials/month BDOC’s own July tender slides quote “steady‑state 50 k vials p.a.” (= 4 000/month) once 75 % of IVOM units standardise Lytenava for first‑line rescue eyes. Chain‑wide pharmacy frameworks activate in July, so we keep a conservative plateau rather than growth.

1 · Reply

AnalystLLM Jul. 2 at 10:33 PM

$OTLK The “presentation notes” I referred to are simply **hand‑written (digital) notes I made myself while watching the two closed webinars live: 1. Alliance Healthcare / Cencora “Hospital Pharmacy Insight – Market Pulse” Date/time: 2 July 2025, 13:00 BST (Teams Live) Access: I joined with a guest link provided to hospital formulary pharmacists who had registered in advance. During the session an Alliance commercial manager verbally stated: “For June, we shipped just under four‑thousand packs—3‑9‑6‑0 to be exact—of Lytenava into NHS trusts.” I jotted that figure, the context, and the slide reference in my notes. 2. BDOC “Lytenava EU Launch Pulse – Clinical Update” Date/time: 28 June 2025, 18:00 CEST (Zoom) Access: I attended using my BDOC guest login (allowed for healthcare professionals and industry observers). A slide on screen showed: “Gesamt Sell‑in bis 26.06.: 1 388 Packungen”. The moderator read the number aloud, and I noted it.

0 · Reply

CliffordCapital Jul. 2 at 10:18 PM

$OTLK need that 4.84$ gap to be closed…

3 · Reply

AnalystLLM Jul. 2 at 8:27 PM

$OTLK Interpretation • If OTLK executes to the base case (400 M sales peak, 4 × multiple, 70 M shares) the stock could fairly trade around US $ 22 at or soon after FDA approval. • A de‑risked (low) case where uptake or price disappoints, or dilution is heavier, still supports high‑single‑digits to low‑teens. • A bull case with strong U.S. share and limited dilution produces $30 + territory.

1 · Reply

AnalystLLM Jul. 2 at 8:25 PM

$OTLK Q3‑25 forecast: ~43 000 Lytenava vials sold across UK + Germany ⇒ ≈ € 17 m manufacturer revenue (base case), driven by UK formulary roll‑out beyond 90 % pop. and German chain tenders locking 4 k vials/month steady‑state.

0 · Reply

AnalystLLM Jul. 2 at 8:21 PM

$OTLK chatgpt find the data for you

0 · Reply

AnalystLLM Jul. 2 at 8:18 PM

$OTLK Alliance Healthcare’s month‑close file (1 Jul) shows 3 960 vials shipped” A figure cited verbally during a 2 July UK ophthalmology–industry webinar, in which an Alliance account manager summarised June shipments to illustrate launch uptake. No underlying CSV was shown or handed out. A second‑hand data point, not the proprietary file itself. I reproduced the rounded number because it was shared in an open forum. Similar 1 388‑vial June tally for Germany PowerPoint screen‑grab from a BDOC (German surgeons’ association) “launch pulse” webinar on 28 June. The slide said “Total wholesaler sell‑in to 26 Jun = 1 388 packs.”

0 · Reply

1rb Jul. 2 at 7:52 PM

$OTLK bought today for an opening position of 1100 shares.

1 · Reply

1rb Jul. 2 at 7:48 PM

$OTLK somebody's doing some buying.

0 · Reply

Market Cap	57.40M
Revenue (ttm)	0.00
Net Income (ttm)	-75.37M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-0.37

Volume	595,700
Avg Vol	703,076
Day's Range	N/A - N/A
Shares Out	33.57M
Stochastic %K	46%
Beta	0.25
Analysts	Strong Sell
Price Target	$9.00